ESR1 and breast carcinoma: Other frequently selected features in both non-metastatic as well as metastatic patients included genes such as the epithelial-to-mesenchymal-transition (EMT)-related gene VIM (46/58 non-metastatic, 30/39 metastatic patients), the extracellular matrix protein FN1 (43/58 non-metastatic, 22/39 metastatic patients), the actin cytoskeleton regulator CFL1 (7/58 non-metastatic, 7/39 metastatic patients), and the estrogen receptor ESR1 28/58 non-metastatic, 10/39 metastatic patients) that are all known to be linked with breast cancer development and progression [45–48].